AGM approves re-appointment of Whole-time Director and cost auditor for FY 2026-27
Re-appointment of Mr. Mohan Kumar Rayana (DIN: 07878975) as Whole-time Director, and his continuation beyond the age of 70, from 21st August 2026 up to 20th August 2031.
- Director Re-appointment
- Mr. Mohan Kumar Rayana (DIN: 07878975) as Whole-time Director, 21st August 2026 up to 20th August 2031
- Director Experience
- Over 25 years engaged with Wanbury, over two decades of pharma experience
- Cost Auditor Appointment
- M/s. ABK & Associates, Cost Accountant, for FY 2026-2027
- Cost Auditor Experience
- Established in 1989, over 35 years of professional experience across industries including pharmaceuticals
- AGM Date
- September 24, 2026
What was approved
Wanbury informed the exchanges that its 38th Annual General Meeting, held on Thursday, September 24, 2026, considered and approved two items.
- Re-appointment of Mr. Mohan Kumar Rayana (DIN: 07878975) as Whole-time Director, and his continuation in that role beyond the age of 70 years, for the period from 21st August 2026 up to 20th August 2031.
- Appointment and ratification of remuneration payable to M/s. ABK & Associates, Cost Accountant, Mumbai, as Cost Auditor of the company for the Financial Year 2026-2027.
About the director
Mr. Mohan is a B. Pharm graduate from the University of Mumbai. He has been engaged with Wanbury for more than 25 years in an advisory role and has over two decades of pharma experience across business strategy, general management, team building, acquisitions and mergers, fund raising and debt settlement. He is not related to any of the directors of the company, and is not debarred from holding the office of director by any order of SEBI or other authority, as confirmed by the Nomination and Remuneration Committee.
About the cost auditor
M/s. ABK & Associates is a firm of Cost Accountants established in 1989, with its head office in Mumbai and branch offices in Indore, Delhi and Vadodara, and over 35 years of professional experience across industries including pharmaceuticals. The firm is not related to any of the directors and is not debarred from holding the office of auditor.
Meeting details
The AGM commenced at 11:30 a.m. and concluded at 12:35 p.m.
How to read this
These are continuity-type governance approvals: an existing senior executive continues in his role for a further five-year term, and a cost auditor is appointed for the coming financial year. There is no change in business operations disclosed here.
Also from Wanbury
New DMF shared in South Africa for Tramadol HCl API; DMFs also shared in Philippines and Singapore
8 Oct 2026
More numbers
- Age threshold for continuation of director70 (Seventy) years
- Director's association with Wanbury in advisory rolemore than 25 years
- Cost audit firm's professional experienceover 35 years
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.